Pulmonx Corporation.
LUNG.US | Manufacture of medical and dental instruments and supplies
Pulmonx Corporation is a commercial-stage medical technology company focused on providing minimally invasive solutions for patients with severe emphysema. Its primary product is the Zephyr Endobronchial Valve, a device used in a procedure called Bronchoscopic Lung Volume Reduction (BLVR). This proce...Show More
Better Health for All
-20
Pulmonx's primary product, the Zephyr Valve, delivers revolutionary health benefits for patients with severe emphysema, including improved lung function, exercise capacity, quality of life, decreased exacerbations, reduced respiratory failure, and improved survival.
1
The FDA approved the Zephyr Valve in June 2018 as a 'breakthrough technology' offering bronchoscopic lung volume reduction without the risks of major surgery.
2
However, clinical studies show significant short-term safety concerns, with a 26.6% pneumothorax rate and a 3.1% death rate in the Zephyr Valve group within 45 days post-procedure in the LIBERATE study.
3
Long-term (46 days-1 year) adverse event rates were lower but still included 6.6% pneumothorax and 23.0% COPD exacerbation.
4
Regarding price accessibility, over 90% of patients nationwide have positive coverage or no access restrictions, and Medicare covers over 95% of qualifying patients.
5
The company offers a Patient Reimbursement Support Program, but no specific pricing or cost-plus data is provided.
6
For risk transparency, the company discusses potential complications like pneumothorax, worsening COPD, hemoptysis, pneumonia, dyspnea, and death in clinical study summaries, but also states that information is subject to change due to complex and frequently changing laws, regulations, rules, and policies.
7
Fair Money & Economic Opportunity
0
No evidence available to assess Pulmonx Corporation on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
-30
Pulmonx Corporation's employee rating on Glassdoor is 3.0 out of 5, based on 17 reviews.
1
The culture and values rating is 2.1 out of 5, and senior management is rated 2.1 out of 5.
2
Only 35% of employees would recommend working at Pulmonx to a friend, and 49% approve of the CEO.
3
The company offers competitive benefits, including self-insured medical plans for its Corporate US employees.
4
However, no specific percentage of the total workforce covered by employer-funded health insurance is provided.
Fair Trade & Ethical Sourcing
0
No evidence available to assess Pulmonx Corporation on Fair Trade & Ethical Sourcing.
Honest & Fair Business
-20
Pulmonx Corporation has a comprehensive Whistleblower Policy, approved by the Board and amended, which encourages employees and third parties to report complaints anonymously via a hotline, email, or mail.
1
The policy includes a non-retaliation clause, and a Compliance Officer tracks complaints, investigations, and resolutions, reporting periodically to the Audit Committee.
2
The company also has an Anti-Corruption Policy, approved by the Board and amended, which applies to all directors, officers, employees, and business partners, prohibiting corrupt payments and requiring accurate accounting.
3
This policy includes third-party due diligence requirements for intermediaries and mandates anti-corruption compliance clauses in written agreements.
4
Seven out of nine (77.78%) of the company's directors are identified as independent.
5
However, only approximately 50% of ethical claims are independently verified with a standardized scope, as evidenced by the requirement for suppliers to provide information on conflict minerals sourcing and Pulmonx's potential request for relevant documents and cooperation with inquiries for its reporting requirements.
Kind to Animals
0
The company's Zephyr Endobronchial Valve System underwent preclinical evaluation using a sheep model, including a 30-day implantation study where at least 12 sheep were used.
1
No further information is available regarding the annual volume of animals used in testing, the company's animal testing policy, or the extent to which non-animal testing methods are employed.
2
There is also no evidence regarding cruelty-free certifications, humane certifications for operations, wildlife conservation impact, ethical input substitution, supplier audit percentages, cage-free sourcing, innovation investment in animal-free technologies, animal agriculture ethics, animal-free R&D collaboration, or public policy engagement related to animal welfare.
3
No War, No Weapons
0
No evidence available to assess Pulmonx Corporation on No War, No Weapons.
Planet-Friendly Business
0
No specific quantitative or qualitative data was found across the provided articles for any of the Planet-Friendly Business KPIs. The articles explicitly state a lack of specific ESG data, including greenhouse gas emissions, renewable energy usage, water consumption, waste diversion, green building certifications, lifecycle impact assessments, or climate-related targets and initiatives.
1
While a '2023 ESG Summary Report' and 'Carbon Reduction Plan' are mentioned, no details or quantitative metrics from these documents are provided to allow for assessment against the rubric's thresholds.
2
Respect for Cultures & Communities
0
No specific, quantitative data points were found across the provided articles to assess Pulmonx Corporation against the 'Respect for Cultures & Communities' ethical value. The articles primarily focused on the company's overall ESG risk rating, corporate governance policies, and product information, explicitly stating a lack of data on community engagement, cultural sensitivity, or related metrics.
1
Safe & Smart Tech
0
No evidence available to assess Pulmonx Corporation on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
No specific, concrete evidence was found in the provided articles regarding Pulmonx Corporation's performance on any of the Zero Waste & Sustainable Products KPIs.
1
The articles explicitly state a lack of data on waste management, product sustainability, or related initiatives, focusing instead on general ESG risk ratings and corporate governance.
2